Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 9:22 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 70 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Aspergers Syndrome Clear all
Completed Not applicable Interventional

RUPP PI PDD: Drug and Behavioral Therapy for Children With Pervasive Developmental Disorders

NCT00080145
View directory record Official record
Conditions
Child Development Disorders, Pervasive
Interventions
Risperidone, Behavior Therapy
Drug · Behavioral
Lead sponsor
Yale University
Other
Eligibility
4 Years to 13 Years
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
3
States / cities
New Haven, Connecticut • Indianapolis, Indiana • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 16, 2013 · Synced Oct 24, 2026, 9:22 AM EDT
Completed Phase 2 Interventional

Citalopram for Children With Autism and Repetitive Behavior (STAART Study 1)

NCT00086645
View directory record Official record
Conditions
Autistic Disorder
Interventions
citalopram hydrobromide, placebo
Drug · Other
Lead sponsor
Boston University
Other
Eligibility
5 Years to 17 Years
Enrollment
149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
6
States / cities
Los Angeles, California • New Haven, Connecticut • Lebanon, New Hampshire + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2017 · Synced Oct 24, 2026, 9:22 AM EDT
Completed Not applicable Interventional

Neural and Behavioral Outcomes of Social Skills Groups in Children With Autism Spectrum Disorder (ASD)

NCT01190917
View directory record Official record
Conditions
Autism, Autism Spectrum Disorder
Interventions
Cognitive Behavioral Therapy (CBT), Play Therapy
Behavioral
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
8 Years to 11 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 2, 2012 · Synced Oct 24, 2026, 9:22 AM EDT
Completed Phase 1Phase 2 Interventional

Cholesterol in ASD: Characterization and Treatment

NCT00965068
View directory record Official record
Conditions
Autism, Asperger Disorder, PDD-NOS
Interventions
Cholesterol
Other
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
4 Years to 12 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 5, 2018 · Synced Oct 24, 2026, 9:22 AM EDT
Recruiting Not applicable Interventional

Transcranial Magnetic Stimulation for Restricted and Repetitive Behavior in ASD

NCT04532424
View directory record Official record
Conditions
Autism Spectrum Disorder, Autism, Asperger Syndrome
Interventions
Transcranial magnetic stimulation
Device
Lead sponsor
Stanford University
Other
Eligibility
12 Years to 45 Years
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Aug 19, 2025 · Synced Oct 24, 2026, 9:22 AM EDT
Active, not recruiting No phase listed Observational

Phenotypic and Genetic Factors in Autism Spectrum Disorders

NCT00910559
View directory record Official record
Conditions
Autism Spectrum Disorders
Interventions
Not listed
Lead sponsor
Boston Children's Hospital
Other
Eligibility
18 Months and older
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2030
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 29, 2025 · Synced Oct 24, 2026, 9:22 AM EDT
Completed Phase 2 Interventional Results available

An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)

NCT01592786
View directory record Official record
Conditions
Autism Spectrum Disorder (ASD), Autism, Autistic Disorder, Asperger's Disorder, Asperger's, Pediatric Autism, Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
Interventions
Memantine Hydrochloride (HCl)
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
6 Years to 12 Years
Enrollment
906 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
72
States / cities
Dothan, Alabama • Phoenix, Arizona • Tucson, Arizona + 63 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2014 · Synced Oct 24, 2026, 9:22 AM EDT
Withdrawn No phase listed Observational

Using the Digital EEG Spectral Analysis in Assessing Neuroelectrical Processing Abnormalities in Autism

NCT00693953
View directory record Official record
Conditions
Autistic Disorder, Autism, Early Infantile, Autism, Infantile, Asperger Syndrome
Interventions
Not listed
Lead sponsor
Yellen & Associates, Inc.
Other
Eligibility
5 Years to 25 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Northridge, California
Source: ClinicalTrials.gov public record
Updated Oct 2, 2009 · Synced Oct 24, 2026, 9:22 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Cognitive Behavioral Therapy for Anxiety Disorders in Adolescents With Autism

NCT01563003
View directory record Official record
Conditions
Autism, Asperger's Syndrome, Pervasive Developmental Disorder Not Otherwise Specified, Generalized Anxiety Disorder, Social Phobia, Separation Anxiety Disorder, Obsessive-compulsive Disorder
Interventions
Cognitive Behavioral Therapy, Treatment as usual
Other
Lead sponsor
University of South Florida
Other
Eligibility
11 Years to 16 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
1
States / cities
St. Petersburg, Florida
Source: ClinicalTrials.gov public record
Updated Apr 17, 2015 · Synced Oct 24, 2026, 9:22 AM EDT
Completed No phase listed Observational

Predictors of Caregiver Adaptation to Pervasive Developmental Disorders

NCT00496210
View directory record Official record
Conditions
Autism, Asperger's Syndrome, Rett's Disorder
Interventions
Not listed
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
18 Years and older
Enrollment
324 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 15, 2019 · Synced Oct 24, 2026, 9:22 AM EDT
Not listed Phase 4 Interventional

An Open-Label Study to Evaluate the Efficacy of High-Dose Gammaplex in Children on the Autism Spectrum

NCT02199925
View directory record Official record
Conditions
Autism, Autistic Disorder, Asperger's Disorder, PDD, Pervasive Developmental Disorder
Interventions
Gammaplex 5%
Drug
Lead sponsor
Isaac Melamed
Industry
Eligibility
4 Years to 12 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Centennial, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 16, 2015 · Synced Oct 24, 2026, 9:22 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Cognitive Behavioral Therapy (CBT) for Anxiety Disorders in Autism: Adapting Treatment for Adolescents

NCT01177969
View directory record Official record
Conditions
Anxiety Disorders in Youth With Autism, Asperger's Syndrome, and Pervasive Developmental Disorder Not Otherwise Specified
Interventions
Cognitive-Behavioral Therapy, Wait-list
Behavioral
Lead sponsor
University of South Florida
Other
Eligibility
11 Years to 14 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2014
U.S. locations
2
States / cities
Los Angeles, California • St. Petersburg, Florida
Source: ClinicalTrials.gov public record
Updated Jul 1, 2014 · Synced Oct 24, 2026, 9:22 AM EDT
Completed Not applicable Interventional

Cognitive-Behavioral Therapy for Irritability in Adolescents With High Functioning Autism Spectrum Disorder

NCT01631851
View directory record Official record
Conditions
Autism, Autism Spectrum Disorder (ASD, Asperger's Disorder, Pervasive Developmental Disorder (PDD-NOS)
Interventions
Cognitive-Behavioral Therapy (CBT) for Irritability
Behavioral
Lead sponsor
Yale University
Other
Eligibility
9 Years to 16 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 18, 2023 · Synced Oct 24, 2026, 9:22 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

TMS for the Investigation of Brain Plasticity in Autism Spectrum Disorders

NCT02836405
View directory record Official record
Conditions
Autism Spectrum Disorder, Intellectual Disability
Interventions
Transcranial Magnetic Stimulation
Device
Lead sponsor
Boston Children's Hospital
Other
Eligibility
6 Years to 65 Years
Enrollment
164 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2020
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 4, 2020 · Synced Oct 24, 2026, 9:22 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Services to Enhance Social Functioning in Adults With Autism Spectrum Disorders

NCT04788537
View directory record Official record
Conditions
Autism, Autism Spectrum Disorder, Autistic Disorder, Asperger Syndrome, Pervasive Developmental Disorder
Interventions
Training to Understand and Navigate Emotions and Interactions (TUNE In)
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 21, 2025 · Synced Oct 24, 2026, 9:22 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

D-Cycloserine and Social Skills Training in Autism Spectrum Disorders

NCT01086475
View directory record Official record
Conditions
Autistic Disorder, Asperger's Disorder, Pervasive Developmental Disorder NOS
Interventions
D-cycloserine, Placebo
Drug
Lead sponsor
Indiana University
Other
Eligibility
5 Years to 11 Years
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
2
States / cities
Indianapolis, Indiana • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 14, 2016 · Synced Oct 24, 2026, 9:22 AM EDT
Terminated Phase 2 Interventional Results available

Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)

NCT01592773
View directory record Official record
Conditions
Autism Spectrum Disorder (ASD), Autism, Autistic Disorder, Asperger's Disorder, Asperger's, Pediatric Autism, Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
Interventions
Memantine Hydrochloride (HCl)
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
6 Years to 12 Years
Enrollment
747 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
68
States / cities
Dothan, Alabama • Phoenix, Arizona • Tucson, Arizona + 62 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2015 · Synced Oct 24, 2026, 9:22 AM EDT
Completed Not applicable Interventional Results available

Intranasal Oxytocin for the Treatment of Autism Spectrum Disorders

NCT01337687
View directory record Official record
Conditions
Autism Spectrum Disorders
Interventions
Intranasal Oxytocin, Placebo
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years to 55 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Feb 27, 2020 · Synced Oct 24, 2026, 9:22 AM EDT
Completed Phase 2 Interventional Results available

A Study of Oral N-Acetylcysteine in Children With Autism Spectrum Disorders

NCT00453180
View directory record Official record
Conditions
Autistic Disorder, Asperger Syndrome, Child Development Disorders, Pervasive
Interventions
N-acetylcysteine, Placebo
Drug
Lead sponsor
Indiana University
Other
Eligibility
4 Years to 12 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jun 14, 2017 · Synced Oct 24, 2026, 9:22 AM EDT
Terminated Not applicable Interventional Results available

Memantine in Adult Autism Spectrum Disorder

NCT01078844
View directory record Official record
Conditions
Autism, Asperger's Disorder, Pervasive Developmental Disorder NOS
Interventions
memantine, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 85 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 26, 2017 · Synced Oct 24, 2026, 9:22 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Neurocircuitry of Autism- fMRI and Transcranial Magnetic Stimulation Studies

NCT01553240
View directory record Official record
Conditions
Autism Spectrum Disorder, Asperger Disorder, Pervasive Developmental Disorder
Interventions
TMS and functional MRI (Magstim)
Device
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 55 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 13, 2017 · Synced Oct 24, 2026, 9:22 AM EDT
Completed Phase 2 Interventional

Study of Arbaclofen for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders

NCT01288716
View directory record Official record
Conditions
Autism Spectrum Disorders
Interventions
Arbaclofen
Drug
Lead sponsor
Seaside Therapeutics, Inc.
Industry
Eligibility
5 Years to 21 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
24
States / cities
Phoenix, Arizona • Los Angeles, California • Sacramento, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2013 · Synced Oct 24, 2026, 9:22 AM EDT
Completed Phase 1Phase 2 Interventional

My Scrivener® - Measuring Effectiveness and Dose Response in Children

NCT00919906
View directory record Official record
Conditions
Asperger's Syndrome, Dyslexia, Cerebral Palsy, Attention Deficit Disorder, ADHD, Traumatic Brain Injury, Stroke
Interventions
My Scrivener(R)
Device
Lead sponsor
Obslap Research LLC
Industry
Eligibility
5 Years to 19 Years
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Eugene, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 28, 2010 · Synced Oct 24, 2026, 9:22 AM EDT
Completed Phase 2 Interventional Results available

Study of Lurasidone in Treating Antipsychotic Naive or Quasi-Naive Children and Adolescents

NCT01731119
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Psychosis NOS, Autistic Disorder, Asperger Syndrome, Child Development Disorders, Pervasive, Bipolar I Disorder, Bipolar II Disorder, Mood Disorder NOS, Severe Major Depression With Psychotic Features, Single Episode Major Depression Without Psychotic Symptoms, Severe Mood Disorder With Psychotic Features
Interventions
Latuda©
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
6 Years to 19 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 14, 2017 · Synced Oct 24, 2026, 9:22 AM EDT